Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
1.
Molecules ; 27(7)2022 Mar 29.
Artigo em Inglês | MEDLINE | ID: mdl-35408620

RESUMO

The present study was designed to examine the efficacy and protection mechanisms of sea buckthorn sterol (SBS) against acute liver injury induced by carbon tetrachloride (CCl4) in rats. Five-week-old male Sprague-Dawley (SD) rats were divided into six groups and fed with saline (Group BG), 50% CCl4 (Group MG), or bifendate 200 mg/kg (Group DDB), or treated with low-dose (Group LD), medium-dose (Group MD), or high-dose (Group HD) SBS. This study, for the first time, observed the protection of SBS against CCl4-induced liver injury in rats and its underlying mechanisms. Investigation of enzyme activities showed that SBS-fed rats exhibited a significant alleviation of inflammatory lesions, as evidenced by the decrease in cyclooxygenase-2 (COX-2), prostaglandin E2 (PGE2), and gamma-glutamyl transpeptidase (γ-GT). In addition, compared to the MG group, the increased indices (superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), catalase (CAT), total antioxidant capacity (T-AOC), and total protein (TP)) of lipid peroxidation and decreased malondialdehyde (MDA) in liver tissues of SBS-treated groups showed the anti-lipid peroxidation effects of SBS. Using the wide range of targeted technologies and a combination of means (UPLC-MS/MS detection platform, self-built database, and multivariate statistical analysis), the addition of SBS was found to restore the expression of metabolic pathways (e.g., L-malic acid, N-acetyl-aspartic acid, N-acetyl-l-alanine, etc.) in rats, which means that the metabolic damage induced by CCl4 was alleviated. Furthermore, transcriptomics was employed to analyze and compare gene expression levels of different groups. It showed that the expressions of genes (Cyp1a1, Noct, and TUBB6) related to liver injury were regulated by SBS. In conclusion, SBS exhibited protective effects against CCl4-induced liver injury in rats. The liver protection mechanism of SBS is probably related to the regulation of metabolic disorders, anti-lipid peroxidation, and inhibition of the inflammatory response.


Assuntos
Doença Hepática Crônica Induzida por Substâncias e Drogas , Doença Hepática Induzida por Substâncias e Drogas , Hippophae , Alanina Transaminase/metabolismo , Animais , Antioxidantes/farmacologia , Tetracloreto de Carbono/efeitos adversos , Doença Hepática Induzida por Substâncias e Drogas/tratamento farmacológico , Doença Hepática Induzida por Substâncias e Drogas/metabolismo , Doença Hepática Induzida por Substâncias e Drogas/prevenção & controle , Doença Hepática Crônica Induzida por Substâncias e Drogas/tratamento farmacológico , Cromatografia Líquida , Hippophae/metabolismo , Peroxidação de Lipídeos , Fígado , Masculino , Estresse Oxidativo , Extratos Vegetais/farmacologia , Ratos , Ratos Sprague-Dawley , Esteróis/farmacologia , Espectrometria de Massas em Tandem
2.
Pak J Pharm Sci ; 33(2): 669-674, 2020 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-32276913

RESUMO

Analysis of the constituents of the chloroform extract of Oxytropis falcata Bunge (CEOF), a traditional Tibetan medicine, in rat's serum after oral administration, has been performed by HPLC-MS. We have identified 10 compounds in CEOF and 11 bioactive ingredients from rat's serum after given CEOF. Six bioactive ingredients from rat's serum are matched with original form of the compounds of CEOF. Other five bioactive ingredients were seemed to be respectively metabolites. HPLC-MS is rapid, sensitive method and suitable for identification of bioactive components absorbed into blood of CEOF providing information for further research of pharmacological mechanism.


Assuntos
Clorofórmio/análise , Clorofórmio/química , Oxytropis , Extratos Vegetais/análise , Extratos Vegetais/química , Espectrometria de Massas em Tandem/métodos , Animais , Cromatografia Líquida de Alta Pressão/métodos , Feminino , Masculino , Microssomos Hepáticos/química , Microssomos Hepáticos/metabolismo , Ratos , Ratos Sprague-Dawley
3.
Gut Liver ; 13(3): 342-348, 2019 05 15.
Artigo em Inglês | MEDLINE | ID: mdl-30600675

RESUMO

Background/Aims: Sorafenib remains the only approved molecular targeted agent for hepatocellular carcinoma (HCC); however, reliable biomarkers that predict its efficacy are still lacking. The aim of this study was to explore whether cancer stem cell (CSC) markers have a predictive role with regard to the sorafenib response in HCC patients. Methods: We enrolled 47 patients with HCC for whom tumor samples obtained before starting sorafenib treatment were available. RNA was extracted from formalin-fixed, paraffin-embedded samples, and real-time polymerase chain reaction was used to quantify mRNA expression of the CSC genes EpCAM, CD13, CK8, CD24, CD44, CD90, CD133, SALL4, ALDH1A1, ALB, and AFP . Results: Of 47 patients, 14.9% and 74.5% had vascular invasion and extrahepatic spread, respectively. Patients with low CD133 expression tended to have longer progression-free survival (PFS) than those with high CD133 expression (5.5 months vs 4.0 months), although without statistical significance. The expression levels of other markers were not associated with PFS. When examining markers in combination, patients with high CD133 and CD90 expression had shorter PFS rates than those with low expression (2.7 months vs 5.5 months; p=0.04). Patients with low CD133 and EpCAM expression demonstrated better PFS than those with high expression (7.0 months vs 4.2 months; p=0.04). Multivariable analysis indicated that an Eastern Cooperative Oncology Group performance status score of 1 and high CD133/CD90 expression were significantly associated with shorter PFS. Conclusions: Overexpression of the CSC markers CD133 and CD90 in HCC was associated with poorer response to sorafenib. These two genes may serve as predictive biomarkers for sorafenib therapy.


Assuntos
Antineoplásicos/uso terapêutico , Carcinoma Hepatocelular/tratamento farmacológico , Neoplasias Hepáticas/tratamento farmacológico , Células-Tronco Neoplásicas/metabolismo , Sorafenibe/uso terapêutico , Adulto , Idoso , Biomarcadores Tumorais/genética , Carcinoma Hepatocelular/genética , Feminino , Humanos , Neoplasias Hepáticas/genética , Masculino , Pessoa de Meia-Idade , Testes Farmacogenômicos , RNA Mensageiro/metabolismo , Resultado do Tratamento
4.
Ophthalmic Res ; 54(2): 85-95, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-26278282

RESUMO

BACKGROUND/AIMS: The present study addresses the role of tonicity response element binding protein (TonEBP) in retinal ganglion cell (RGC) death in diabetic retinopathy and the impact of Aralia elata extract on the TonEBP/RGC interaction. METHODS: Diabetes was induced in C57BL/6 mice by intraperitoneal injection of streptozotocin (STZ). Control mice received phosphate-buffered saline. After five injections of STZ or saline buffer, A. elata extract was administered by daily oral tube feeding for 7 weeks. All mice were killed at 2 months after the last injection of STZ or saline and the extent of cell death together with the protein expression levels of TonEBP, aldose reductase (AR) and nuclear factor-kappa B (NF-κB) were examined. RESULTS: Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL)-positive signals were colocalized with TonEBP-immunoreactive RGCs. The apoptotic cell death of RGCs and the expression levels of TonEBP, AR and NF-κB were significantly increased in the retinas of diabetic mice compared with controls at 2 months after the induction of diabetes. However, these changes were effectively blocked by the administration of A. elata extract. CONCLUSIONS: These results indicate that A. elata prevents diabetes-induced RGC apoptosis and downregulates TonEBP expression. Therefore, A. elata extract may have therapeutic potential to prevent diabetes-induced retinal neurodegeneration in diabetic retinopathy.


Assuntos
Aralia , Diabetes Mellitus Experimental/complicações , Retinopatia Diabética/metabolismo , Fatores de Transcrição NFATC/metabolismo , Extratos Vegetais/farmacologia , Células Ganglionares da Retina/efeitos dos fármacos , Animais , Apoptose/efeitos dos fármacos , Retinopatia Diabética/tratamento farmacológico , Regulação para Baixo , Camundongos , Camundongos Endogâmicos C57BL , Retina/efeitos dos fármacos , Retina/metabolismo , Células Ganglionares da Retina/metabolismo
5.
J Med Food ; 16(7): 569-76, 2013 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-23822143

RESUMO

Needles of pine species are rich in polyphenols, which may exert beneficial effects on human health. The present study was conducted to evaluate the in vitro and in vivo antioxidant effects of Pinus koraiensis needle water extracts (PKW). HepG2 cells were pretreated with various concentrations of PKW (from 10(-3) to 1 mg/mL) and oxidative stress was induced by tert-butyl hydroperoxide (t-BOOH). In the animal model, male ICR mice were fed a high-fat diet for 6 weeks to induce obesity, and then mice were continually fed a high-fat diet with or without orally administered PKW (400 mg/kg body weight) for 5 weeks. Pretreatment with PKW prevented significant increases in cytotoxicity and catalase activity induced by t-BOOH in HepG2 cells. Similarly, the catalase protein expression levels elevated by t-BOOH were abrogated in cells pretreated with PKW. In mice fed a high-fat diet, PKW significantly increased hepatic activities of catalase and glutathione reductase and lower lipid peroxidation levels were observed in the liver and kidney of mice with PKW supplementation. The present study demonstrates that PKW protects against oxidative stress in HepG2 cells treated with t-BOOH and in mice fed a high-fat diet.


Assuntos
Estresse Oxidativo/efeitos dos fármacos , Pinus/química , Extratos Vegetais/administração & dosagem , Animais , Antioxidantes/administração & dosagem , Catalase/genética , Catalase/metabolismo , Glutationa Redutase/metabolismo , Células Hep G2 , Humanos , Peroxidação de Lipídeos/efeitos dos fármacos , Fígado/efeitos dos fármacos , Fígado/metabolismo , Masculino , Camundongos , Camundongos Endogâmicos ICR , Camundongos Obesos , Obesidade/tratamento farmacológico , Obesidade/genética , Obesidade/metabolismo , Folhas de Planta/química
6.
Int J Radiat Oncol Biol Phys ; 81(5): e743-8, 2011 Dec 01.
Artigo em Inglês | MEDLINE | ID: mdl-21129857

RESUMO

PURPOSE: In patients with pancreatic cancer treated with curative resection, we evaluated the effect of clinicopathologic parameters on early distant metastasis within 6 months (DM6m) to identify patients who might benefit from surgery. METHODS AND MATERIALS: The study involved 84 patients with pancreatic cancer who had undergone curative resection between August 2001 and April 2009. The parameters of gender, age, tumor size, histologic differentiation, T classification, N classification, pre- and postoperative carbohydrate antigen (CA) 19-9 level, resection margin, and adjuvant chemoradiotherapy were analyzed to identify the risk factors associated with DM6m. RESULTS: Of the 84 patients, locoregional recurrence developed in 35 (41.7%) and distant metastasis in 58 (69%). Of the 58 patients with distant metastasis, DM6m had developed in 27 (46.6%). Multivariate analysis showed that preoperative CA 19-9 level was significantly associated with DM6m (p<.05). Of all 84 patients, DM6m was observed in 9.1%, 50%, and 80% of those with a preoperative CA 19-9 level of ≤100 U/mL, 101-400 U/mL, and >400 U/mL, respectively (p<.001). CONCLUSIONS: The preoperative CA 19-9 level might be a useful predictor of DM6m and to identify those who would benefit from surgical resection.


Assuntos
Antígeno CA-19-9/sangue , Metástase Neoplásica , Neoplasias Pancreáticas/patologia , Neoplasias Pancreáticas/cirurgia , Adulto , Idoso , Idoso de 80 Anos ou mais , Análise de Variância , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Capecitabina , Quimiorradioterapia , Desoxicitidina/administração & dosagem , Desoxicitidina/análogos & derivados , Feminino , Fluoruracila/administração & dosagem , Fluoruracila/análogos & derivados , Humanos , Leucovorina/administração & dosagem , Masculino , Pessoa de Meia-Idade , Neoplasias Pancreáticas/sangue , Neoplasias Pancreáticas/mortalidade , Neoplasias Pancreáticas/terapia , Dosagem Radioterapêutica , Estudos Retrospectivos
7.
Korean J Physiol Pharmacol ; 13(4): 287-93, 2009 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-19885012

RESUMO

The dried roots of Danshen (Salvia miltiorrhiza) and Sanchi (Panax notoginseng) have been widely used in traditional Chinese medicine for promoting blood circulation as well as various other bodily functions. Here we investigated the effects of a mixture of aqueous extracts of Danshen and Sanchi, named PASEL, on blood pressure and vascular contractility in rats. Orally administered PASEL (62.5 mg/kg and 250 mg/kg, for 5 weeks) lowered the blood pressure of spontaneous hypertensive rats (SHR) but this was not observed in normal Wistar-Kyoto rats (WKR). We then investigated the effects of PASEL on the arterial contraction of the small branches of cerebral arteries (CAs) and large conduit femoral arteries (FAs) in rats. PASEL did not affect high-K (KCl 60 mM)- or phenyleprine (PhE)-induced contracture of FAs. The myogenic response, a reactive arterial constriction in response to increased luminal pressure, of small CA was dose-dependently suppressed by PASEL in SHR as well as control rats. Interestingly, the KCl-induced contraction of small CAs was slowly reversed by PASEL, and this effect was more prominent in SHR than control WKR. PASEL did not inhibit angiotensin-converting enzyme (ACE) activity. These results demonstrated that the antihypertensive effect of PASEL might be primarily mediated by altering the arterial MR, not by direct inhibition of L-type Ca(2+) channels or by ACE inhibition.

8.
J Thorac Oncol ; 1(9): 965-71, 2006 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-17409980

RESUMO

PURPOSE: This prospective trial was conducted to evaluate the role of gefitinib in never-smokers with advanced or metastatic adenocarcinoma of the lung. PATIENTS AND METHODS: The main inclusion criteria were stage IIIB/IV adenocarcinoma of the lung and status as a lifetime never-smoker. Patients received a 250-mg single oral daily dose of gefitinib until disease progression, unacceptable toxicity, or patient's refusal. Tumor response was assessed after every two 4-week cycles according to the World Health Organization response criteria. Additional analyses were performed to identify predictors of response and survival. RESULTS: Between August 2003 and March 2005, 72 Korean patients were enrolled; 55 chemotherapy naive, 17 previously treated; 6 male, 66 female; and ECOG PS 0/1/2, 24/42/4. All patients were assessed for response, toxicity, quality of life, and survival. Overall objective tumor response rate was 55.6% (95% confidence interval [CI], 43.4-67.3%). With a median follow-up of 23 months, the median survival time was 19.7 months (95% CI, 18.5-21.0 months) with a 1-year survival rate of 76.3%. The median duration of response was 6.8 months (95% CI, 4.7-9.0 months). Therapy-related improvement of symptoms and quality of life was observed within 2 to 4 weeks after the commencement of therapy in the responders. In a multivariate Cox proportional hazard model, good performance status and no prior history of chemotherapy were the two significant predictors of better survival (p = 0.005 and 0.042). CONCLUSION: Gefitinib showed very promising antitumor activity and survival outcome in Korean never-smokers with adenocarcinoma of the lung. It seems to be a good alternative to standard chemotherapy as a first-line therapy for this subgroup.


Assuntos
Adenocarcinoma/tratamento farmacológico , Adenocarcinoma/mortalidade , Neoplasias Pulmonares/tratamento farmacológico , Neoplasias Pulmonares/mortalidade , Invasividade Neoplásica/patologia , Quinazolinas/administração & dosagem , Adenocarcinoma/patologia , Administração Oral , Idoso , Biópsia por Agulha , Relação Dose-Resposta a Droga , Esquema de Medicação , Feminino , Seguimentos , Gefitinibe , Humanos , Imuno-Histoquímica , Coreia (Geográfico) , Neoplasias Pulmonares/patologia , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Estadiamento de Neoplasias , Probabilidade , Prognóstico , Modelos de Riscos Proporcionais , Estudos Prospectivos , Qualidade de Vida , Medição de Risco , Método Simples-Cego , Fumar , Taxa de Sobrevida , Resultado do Tratamento
9.
J Ethnopharmacol ; 101(1-3): 49-54, 2005 Oct 03.
Artigo em Inglês | MEDLINE | ID: mdl-15905053

RESUMO

The water extract of Aralia elata (Aralia extract) has been used in Korean traditional medicine to treat diabetes mellitus. Here, we investigated the aldose reductase inhibitory activity, antioxidant activity and anticataract capacity of Aralia extract using various experimental systems. To determine its aldose reductase inhibitory activity and its antioxidant effect, we used rat lens homogenates. Rat lens cultures and a rat model were used to observe anticataract activity. The resulting IC50 value of Aralia extract in vitro as an aldose reductase inhibitor was 11.3 microg/ml and as an antioxidant was 25.1 microg/ml. Rat lenses in media containing 20 mM xylose developed a distinctly opaque ring in 9h, and treatment with Aralia extract at a concentration of 1mg/ml lowered lens opacity by 36.4 and 31.3% after 24 and 48 h, respectively. In vivo experiments were performed with streptozotocin (STZ) induced diabetic rats. The diabetic control animals developed cataracts at 11 weeks after STZ injection, while oral Aralia extract administered at 300 and 600 mg/kg body weight for 11 weeks reduced cataract formation by 15 and 12%, respectively. The present study shows that Aralia extract inhibits aldose reductase and acts in vitro as an antioxidant, and suggests that these activities have a preventive effect on cataractogenesis in xylose containing lens organ cultures and in in vivo in STZ induced diabetic rats.


Assuntos
Aralia , Catarata/prevenção & controle , Fitoterapia , Extratos Vegetais/uso terapêutico , Aldeído Redutase/antagonistas & inibidores , Animais , Antioxidantes/farmacologia , Diabetes Mellitus Experimental/tratamento farmacológico , Masculino , Extratos Vegetais/farmacologia , Ratos , Ratos Sprague-Dawley , Estreptozocina
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA